Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This research discusses the parallel clinical development of ritlecitinib, an oral Janus kinase 3/tyrosine kinase inhibitor, for treating conditions such as alopecia areata, vitiligo, ulcerative colitis, Crohn's disease, and rheumatoid arthritis. Results are not reported in the abstract.

This study found that patients with alopecia areata had significantly higher serum levels of IL-1α compared to healthy controls, with no significant difference observed in IL-1β levels.

This study found that ion-paired solutions significantly improved the skin penetration of risedronate in hairless mice compared to risedronate alone.

In this case report, two patients with coexisting systemic lupus erythematous and neuromyelitis optica spectrum disorder achieved remission of SLE activity using an anti-CD19 monoclonal antibody.

This review explored treatment options for alopecia areata in the military health care system, evaluating the pathogenesis and impact of the condition as well as the efficacy and safety of FDA-approved JAK inhibitors, baricitinib and ritlecitinib.

This article reviews the therapeutic use of interferons and other cytokines in various viral, tumorous, and inflammatory diseases, discussing their biological effects and potential future applications without presenting new experimental results.

This study indicates that innate lymphoid cells-type 1 may provoke alopecia areata by disrupting hair follicle immune privilege and inducing characteristic lesions, challenging the view that alopecia areata is purely an autoantigen-dependent, T cell-driven condition.

This study explored the effectiveness of the oral JAK1/2 inhibitor ruxolitinib in treating patients with moderate-to-severe alopecia areata, building on prior success with JAK inhibitors in mice, but results are not reported in this abstract.

This review suggests that IL-23 inhibitors may be effective for various non-psoriatic inflammatory skin conditions, but emphasizes the need for further large-scale trials to confirm their efficacy and safety.

Baricitinib reduces inflammation and mitochondrial damage in skin cells.

In this phase 1B study, patients with ER-positive/HER2-negative metastatic breast cancer receiving combined pegylated liposomal doxorubicin and pembrolizumab had a disease control rate of 67% with responses lasting a median of 11 months; the treatment was well tolerated and showed potential for extended use.

This study reported that Sintilimab combined with chemotherapy may improve outcomes in advanced NSCLC patients but carries a higher risk of certain side effects, including hypothyroidism.

JAK inhibitors, like baricitinib and ritlecitinib, show promise in treating alopecia areata effectively and safely.

This study found that platelet-rich fibrin lysates modulate chemokine expression, reducing inflammation in oral squamous carcinoma cells, but increasing expression in primary oral epithelial cells.

This study found that IL-6 knockout mice exhibited increased wound-induced hair neogenesis compared to wild-type mice, likely due to enhanced STAT3 activation facilitated by compensatory cytokine activity.

In this study, researchers found that ritlecitinib, a JAK3/TEC inhibitor, significantly improves hair regrowth, quality of life, and psychological well-being in patients with severe alopecia areata who had inadequate or no response to baricitinib, a JAK1/2 inhibitor.

This review discusses the role and mechanisms of unconventional lymphocytes in promoting tissue repair and maintaining mucosal barrier integrity in the skin, gut, and lungs, but reports no new findings.

This study evaluated the real-world use of ritlecitinib for severe alopecia areata in the UK, reporting that 37% of patients achieved significant hair regrowth by week 36, with no serious adverse effects noted, although response varied with disease duration.

In this study, Ritlecitinib was reported as a newly approved treatment for alopecia areata that can be used in patients aged 12 and older; after 24 weeks, it resulted in 80% or more scalp hair coverage in treated patients compared to a placebo.

In this study, baricitinib treatment led to significant regrowth of scalp, eyebrow, and eyelash hair in alopecia areata patients compared to placebo, with higher effectiveness seen at the 4-mg dose.

Irradiating the whole central nervous system can lead to over 50% of patients with cerebellar medulloblastoma surviving three years.

This study found that illness perception, as measured by the Revised Illness Perception Questionnaire, was significantly associated with health-related quality of life in patients with primary cutaneous T- and B-cell lymphomas.

This study found that adipose-derived mesenchymal stromal cell secretome, particularly when preconditioned with IFNγ, significantly influences cell motility and anti-inflammatory responses, enhancing its potential as a regenerative therapy.

In this study, single-cell sequencing revealed clonal expansions of CD4+ and CD8+ T cells in murine and human alopecia areata, supporting the development of predictive models for human disease.

This review explores the complex factors involved in alopecia areata, such as immune and genetic influences, and discusses advances in diagnostic and therapeutic approaches, while reporting no new clinical results.

This study found that para-phenylenediamine induces cytotoxic effects in normal human hair dermal papilla cells by altering microRNA expression and causing cell death, cell cycle arrest, and oxidative stress.

This phase II trial found that BI 2536 demonstrated limited antitumor activity across five solid tumor types, with no confirmed objective responses observed.

This report describes a case of a patient with metastatic renal cell carcinoma who developed a psoriasiform skin lesion while undergoing immune checkpoint inhibitor therapy.